It was thus possible to further enhance the efficacy of aDabi-Fab2 based on rational design, giving it the potential to serve as a back-up candidate for idarucizumab.Ī New Biological Entities Discovery Boehringer Ingelheim GmbH & Co. Interestingly, the increased residence time translated into longer duration of action in vivo. It displayed increased affinity for dabigatran, mainly driven by a slower off-rate. RIDGEFIELD, Conn., Ma Today, Boehringer Ingelheim announced that Praxbind ® (idarucizumab), a specific reversal agent for Pradaxa ® (dabigatran etexilate mesylate), a novel oral anticoagulant (NOAC), is now stocked in more than 2,200 hospitals in all fifty states. The mutant had optimized shape complementarity to dabigatran while maintaining an energetically favored hydrogen bond. Rational protein engineering, based on the X-ray structure of aDabi-Fab2, led to the identification of mutant Y103W. Although aDabi-Fab2 completely reversed effects of dabigatran in a rat model in vivo, we observed significantly reduced duration of action compared to idarucizumab. Here, we report data on the antibody fragment aDabi-Fab2, a putative backup molecule for idarucizumab. Idarucizumab is a reversal agent for the direct thrombin inhibitor, dabigatran etexilate (Pradaxa®) and is currently in Phase 3 studies. However, anticoagulation therapy in general is associated with an elevated risk of bleeding. Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. Diversity, Equity, Inclusion, and Access.Biologically Interesting Molecule Reference Dictionary (BIRD).
0 kommentar(er)
